NO20075169L - Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme. - Google Patents

Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.

Info

Publication number
NO20075169L
NO20075169L NO20075169A NO20075169A NO20075169L NO 20075169 L NO20075169 L NO 20075169L NO 20075169 A NO20075169 A NO 20075169A NO 20075169 A NO20075169 A NO 20075169A NO 20075169 L NO20075169 L NO 20075169L
Authority
NO
Norway
Prior art keywords
preparation
pharmaceutical compositions
same
compositions containing
ornamental
Prior art date
Application number
NO20075169A
Other languages
English (en)
Norwegian (no)
Inventor
Marie-Francoise Bordes
Alain Badorc
Francoise Bono
Chantal Alcouffe
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20075169L publication Critical patent/NO20075169L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
NO20075169A 2005-03-16 2007-10-10 Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme. NO20075169L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0502590A FR2883286B1 (fr) 2005-03-16 2005-03-16 NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
PCT/FR2006/000567 WO2006097625A1 (fr) 2005-03-16 2006-03-15 NOUVEAUX DÉRIVÉS D'IMIDAZO[1,5-a]PYRIDINES, LEUR PROCÉDÉ DE PRÉPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT.

Publications (1)

Publication Number Publication Date
NO20075169L true NO20075169L (no) 2007-12-12

Family

ID=35276198

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075169A NO20075169L (no) 2005-03-16 2007-10-10 Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.

Country Status (24)

Country Link
US (2) US8008321B2 (pl)
EP (1) EP1861403B1 (pl)
JP (1) JP5007295B2 (pl)
KR (1) KR101278374B1 (pl)
CN (2) CN102050821A (pl)
AT (1) ATE556074T1 (pl)
AU (1) AU2006224466B2 (pl)
BR (1) BRPI0607589A2 (pl)
CA (1) CA2599643C (pl)
CY (1) CY1112997T1 (pl)
DK (1) DK1861403T3 (pl)
EA (1) EA013408B1 (pl)
ES (1) ES2386643T3 (pl)
FR (1) FR2883286B1 (pl)
IL (1) IL185611A (pl)
MA (1) MA29716B1 (pl)
MX (1) MX2007011361A (pl)
NO (1) NO20075169L (pl)
NZ (1) NZ561205A (pl)
PL (1) PL1861403T3 (pl)
PT (1) PT1861403E (pl)
SI (1) SI1861403T1 (pl)
WO (1) WO2006097625A1 (pl)
ZA (1) ZA200707901B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200804284A (en) * 2006-03-31 2008-01-16 Speedel Experimenta Ag Process for preparing 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one
US7803810B2 (en) 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors
AU2008236649B2 (en) * 2007-04-10 2013-05-02 H. Lundbeck A/S Heteroaryl amide analogues as P2X7 antagonists
WO2009123316A1 (ja) * 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2967412B1 (fr) * 2010-11-17 2012-12-14 Sanofi Aventis Nouveaux derives d'indolizine, leur preparation et leur application en therapeutique
CN103548392B (zh) 2011-07-01 2018-07-06 诺基亚技术有限公司 用于向连接装置提供网络访问的方法和装置
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
WO2014005150A1 (en) * 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
MX2015002959A (es) * 2013-03-10 2015-06-05 Univ Nagoya Nat Univ Corp Agente terapeutico para padecimiento sistemico oseo y uso del mismo.
TW201605832A (zh) 2013-12-10 2016-02-16 克立弗生物科學公司 作為ｐ９７錯合物之抑制劑之單環嘧啶／吡啶化合物
CN103910643B (zh) * 2014-04-23 2015-07-15 温州大学 一种抗癌活性甲酮衍生物、合成方法及其用途
FR3022244B1 (fr) * 2014-06-17 2016-07-01 Centre Nat De La Rech Scient (Cnrs) Utilisation d'un nouveau compose 3-aryl-4-catechol-pyrrole-n-propanol et ses derives pour le traitement du cancer et des pathologies associees a une angiogenese excessive
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
AU2016237222B2 (en) 2015-03-25 2021-04-29 Eisai R&D Management Co., Ltd. Therapeutic agent for bile duct cancer
CN107922396B (zh) * 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
CA3001969C (en) 2015-12-17 2023-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
JPWO2019189241A1 (ja) 2018-03-28 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
CN110483437B (zh) * 2018-05-14 2022-12-06 嘉兴维眸生物科技有限公司 一种含五元环的化合物及其制备和应用
CN110183442A (zh) * 2019-06-06 2019-08-30 无锡合全药业有限公司 一种1 -(乙氧羰基)咪唑并[1, 5]吡啶-6-羧酸的合成方法
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
CN113735849B (zh) * 2021-07-22 2022-10-11 安徽中医药大学 1-氰基咪唑并[1,5-a]吡啶类化合物及其合成方法
CN113603687A (zh) * 2021-08-02 2021-11-05 北京工业大学 一种氰基取代的咪唑[1,5-a]并吡啶合成新方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738647A (en) * 1996-09-27 1998-04-14 Becton Dickinson And Company User activated iontophoretic device and method for activating same
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
AU2006224466A1 (en) 2006-09-21
US8633216B2 (en) 2014-01-21
FR2883286B1 (fr) 2008-10-03
EP1861403B1 (fr) 2012-05-02
SI1861403T1 (sl) 2012-08-31
US8008321B2 (en) 2011-08-30
FR2883286A1 (fr) 2006-09-22
ZA200707901B (en) 2009-01-28
MA29716B1 (fr) 2008-09-01
BRPI0607589A2 (pt) 2009-09-15
IL185611A0 (en) 2008-01-06
EA013408B1 (ru) 2010-04-30
US20110136856A1 (en) 2011-06-09
CY1112997T1 (el) 2016-04-13
MX2007011361A (es) 2007-11-12
KR20070113227A (ko) 2007-11-28
CA2599643A1 (fr) 2006-09-21
CN101160309A (zh) 2008-04-09
IL185611A (en) 2013-11-28
AU2006224466B2 (en) 2012-02-16
KR101278374B1 (ko) 2013-06-25
PT1861403E (pt) 2012-07-20
JP5007295B2 (ja) 2012-08-22
EP1861403A1 (fr) 2007-12-05
WO2006097625A1 (fr) 2006-09-21
ATE556074T1 (de) 2012-05-15
CA2599643C (fr) 2014-02-11
CN102050821A (zh) 2011-05-11
US20080108648A1 (en) 2008-05-08
EA200701991A1 (ru) 2008-02-28
NZ561205A (en) 2009-09-25
PL1861403T3 (pl) 2012-10-31
ES2386643T3 (es) 2012-08-24
DK1861403T3 (da) 2012-08-13
JP2008533111A (ja) 2008-08-21

Similar Documents

Publication Publication Date Title
ATE450533T1 (de) Carboxamidderivate
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MXPA04003007A (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
NO20070339L (no) 1-aza-bicyklo[3 3.1]nonaner
NO20061406L (no) Organiske forbindelser
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
NO20071140L (no) Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
BRPI0408068A (pt) derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase
CY1112084T1 (el) Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3
TW200613243A (en) Novel compounds
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
TW200609204A (en) Sulfonamide derivatives, preparation thereof and therapeutic application thereof
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20061363L (no) Pyrazolo- og imidazo- pyrimidinderivater
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
TW200639156A (en) New compounds
NZ545580A (en) Aminoquinoline derivatives and their use as adenosine A3 ligands
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0401763D0 (sv) Compounds
SI1869038T1 (sl) Substituirane 5,6,7,8-tetrahidro-imidazo(1,2-a)piridin-2-ilaminske spojine in njihova uporaba za pripravo zdravil

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application